Quantitative and Volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors Measurements: Feasibility of a Semiautomated Software Method to Assess Tumor Response after Transcatheter Arterial Chemoembolization

Lin, Ming De; Pellerin, Olivier; Bhagat, Nikhil; Rao, Pramod; Loffroy, Romaric; Ardon, Roberto; Mory, Benoît; Reyes, Diego; Geschwind, Jean François H.

doi:10.1016/j.jvir.2012.08.028

Cited by 89 publications

(97 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Volume measurements are becoming faster, user friendly and widely available thanks to the widespread introduction of new automatic and semiautomatic software for image segmentation [22,23,24]. Indeed, in the present series, the mean postprocessing time was <2 min, and volume measurement was found to be highly reproducible with excellent intra- and interobserver agreement.…”

Section: Discussionmentioning

confidence: 60%

“…In addition, determination of response based on changes in tumor density and perfusion parameters has been proposed, using contrast-enhanced ultrasound, perfusion CT and/or magnetic resonance spectral imaging [14,16,17,18,19,20,21]. Finally, some authors have underlined the need for volumetric assessment of tumor variations to increase accuracy and reproducibility in assessing tumor response in HCC patients [22,23,24]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?

Bargellini

Scionti

Mismas³

et al. 2014

Oncology

View full text Add to dashboard Cite

Objectives: Early assessment of hepatocellular carcinoma (HCC) response during sorafenib (SO) treatment is challenging, since tumor necrosis, extension and radiological appearance can be inhomogeneous. We evaluated the predictive value of different imaging criteria - such as Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, European Association for the Study of the Liver (EASL), modified RECIST (mRECIST), tumor density and volume variations - in the early follow-up of SO treatment. Methods: The study included 22 patients. CT images from baseline and 2 months were reviewed to assess response according to RECIST 1.1, mRECIST, EASL, Choi's criteria (decreased tumor density by ≥15%) and arterial-enhancing tumor volume ratio; α-fetoprotein (AFP) variations were expressed as AFP ratio. Results: The response criteria and volume measurements were reproducible (k > 0.80). The overall disease control rate was 40.9% by EASL and mRECIST, and 27.3% by RECIST 1.1; a ≥15% decrease in tumor density was observed in 9 patients (40.9%). The mean volume ratio was 1.73 ± 2.12, the mean AFP ratio 14 ± 37. The 1-year survival rate was 65.9%. Volume ratio was the only predictive factor for survival, with 1-year cumulative survival rates of 90% for volume ratios ≤1.1 and of 45.4% for volume ratios >1.1 (p = 0.04). Conclusions: Tumor volume measurements are reproducible and might provide an early predictive marker of response in HCC patients treated with SO.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Introductionmentioning

confidence: 99%

Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?

Bargellini

Scionti

Mismas³

et al. 2014

Oncology

View full text Add to dashboard Cite

show abstract

“…Use of volumetry, rather than uni-or bidimensional measurements, can modify classification of tumor response in up to one-third of patients (46,47). A recent study has shown the feasibility of volumetric tumor measurement as well as semiautomatic quantification of tumor enhancement (viable tissue) for hepatocellular carcinoma lesions after TACE (48). Volumetric quantification of hepatocellular carcinoma necrosis has been shown to be more reproducible than the EASL criteria (49) (Fig 11).…”

Section: Volumetric Quantificationmentioning

confidence: 99%

Assessment of Liver Tumor Response to Therapy: Role of Quantitative Imaging

Gonzalez-Guindalini¹,

Botelho²,

Harmath³

et al. 2013

RadioGraphics

View full text Add to dashboard Cite

Quantitative imaging is the analysis of retrieved numeric data from images with the goal of reducing subjective assessment. It is an increasingly important radiologic tool to assess treatment response in oncology patients. Quantification of response to therapy depends on the tumor type and method of treatment. Anatomic imaging biomarkers that quantify liver tumor response to cytotoxic therapy are based on temporal change in the size of the tumors. Anatomic biomarkers have been incorporated into the World Health Organization criteria and the Response Evaluation Criteria in Solid Tumors (RECIST) versions 1.0 and 1.1. However, the development of novel therapies with different mechanisms of action, such as antiangiogenesis or radioembolization, has required new methods for measuring response to therapy. This need has led to development of tumor- or therapy-specific guidelines such as the Modified CT Response Evaluation (Choi) Criteria for gastrointestinal stromal tumors, the European Association for Study of the Liver (EASL) criteria, and modified RECIST for hepatocellular carcinoma, among many others. The authors review the current quantification criteria used in the evaluation of treatment response in liver tumors, summarizing their indications, advantages, and disadvantages, and discuss future directions with newer methods that have the potential for assessment of treatment response. Knowledge of these quantitative methods is important to facilitate pivotal communication between oncologists and radiologists about cancer treatment, with benefit ultimately accruing to the patient.

show abstract

“…In addition, determination of response, based on changes in tumor density and perfusion parameters, has been proposed, using CEUS, perfusion CT, and/or MR spectral imaging [59,[63][64][65][66][67][68]. Finally, some authors have underlined the need for volumetric assessment of tumor variations to increase accuracy and reproducibility in assessing tumor response [69][70][71].…”

Section: Post-treatment Evaluationmentioning

confidence: 99%

Imaging in Hepatocellular Carcinoma: Radiologic Assessment

Bargellini¹,

Battaglia²,

Caramella³

et al. 2015

An Information Technology Framework for Predictive, Preventive and Personalised Medicine

View full text Add to dashboard Cite

In the context of Predictive, Preventive and Personalized Medicine (PPPM), radiologists play an essential role in patient management throughout the different phases of hepatocellular carcinoma (HCC). This includes diagnosis, staging, treatment planning, and evaluation of response to treatment. This chapter provides an in-depth examination of the fundamental pathophysiologic mechanisms underlying the radiologic diagnosis and assessment of HCC. Observations made in contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI), in conjunction with alpha-fetoprotein (AFP) can allow the diagnosis of HCC to be made with confidence without the need for biopsy, in many cases. Treatment decisions and prognosis are strongly influenced by the tumor extension, the number and size of lesions, tumor location, biliary dilatation, ascites, and the presence of macrovascular invasion and extrahepatic tumor spread. In addition, radiologic assessment of co-morbidities and response to previous treatments must be included in the overall assessment. The patient-specific findings from diagnostic imaging and interventional radiology identified in this chapter will be designated as Information Entities (IEs) in later chapters. These IEs will ultimately be used in the generation of Digital Patient Models (DPMs) to facilitate diagnosis, prognosis, and treatment selection, i.e. Model Guided Therapy (MGT) and PPPM.

show abstract

Quantitative and Volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors Measurements: Feasibility of a Semiautomated Software Method to Assess Tumor Response after Transcatheter Arterial Chemoembolization

Cited by 89 publications

References 37 publications

Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?

Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?

Assessment of Liver Tumor Response to Therapy: Role of Quantitative Imaging

Imaging in Hepatocellular Carcinoma: Radiologic Assessment

Contact Info

Product

Resources

About